Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

GILEAD SCIENCES, INC.

(GILD)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Gilead Sciences Swings to 2Q Profit as Revenue Soars 21%

07/29/2021 | 04:30pm EDT

By Kimberly Chin

Gilead Sciences Inc. swung to a profit in the second quarter as revenue increased 21% driven by higher demand for therapies such as remdesivir, Biktarvy and its hepatitis C virus products as well as stronger demand for Trodelvy and Tecartus in the U.S.

The biopharmaceutical company's net profit was $1.52 billion, compared with a loss of $3.34 billion a year earlier. Earnings were $1.21 a share for the quarter, compared with a loss of $2.66 a shaer a year ago. Excluding special items, Gilead posted an adjusted profit of $1.87 a share. Analysts polled by FactSet were expecting adjusted earnings of $1.74 a share.

Total revenue rose to $6.22 billion from $5.14 billion in the year-earlier period. Analysts estimated $6.08 billion in revenue. Sales of its flagship HIV therapy Biktarvy increased by 24% from the prior year.

Write to Kimberly Chin at kimberly.chin@wsj.com

(END) Dow Jones Newswires

07-29-21 1629ET

All news about GILEAD SCIENCES, INC.
08:05aGILEAD SCIENCES : Veklury (Remdesivir) Significantly Reduced Risk of Hospitalization in Hi..
AQ
09/22GILEAD SCIENCES : Veklury Lowers Hospitalization Risk in COVID-19 Patients in Phase 3 Stud..
MT
09/22BROOKLYN IMMUNOTHERAPEUTICS : Names Roger Sidhu Chief Medical Officer
MT
09/22GILEAD SCIENCES : Veklury« (Remdesivir) Significantly Reduced Risk of Hospitalization in H..
BU
09/22Gilead Sciences, Inc. Announces Positive Results from A Phase 3 Randomized, Double-Blin..
CI
09/20GILEAD SCIENCES : to Present Latest Antiviral Research Data Addressing Urgent Global Needs..
BU
09/20Gilead to Present Latest Antiviral Research Data Addressing Urgent Global Needs in Infe..
CI
09/17GILEAD SCIENCES : Trodelvy Significantly Improved Quality of Life Over Standard of Care in..
AQ
09/17GILEAD SCIENCES : New Data Demonstrate Trodelvy Survival Benefit in Metastatic Triple-Nega..
AQ
09/17Gritstone bio, Inc. announced that it has received $55 million in funding from Frazier ..
CI
More news
Analyst Recommendations on GILEAD SCIENCES, INC.
More recommendations
Financials (USD)
Sales 2021 24 999 M - -
Net income 2021 6 525 M - -
Net Debt 2021 23 112 M - -
P/E ratio 2021 14,2x
Yield 2021 3,96%
Capitalization 89 497 M 89 497 M -
EV / Sales 2021 4,50x
EV / Sales 2022 4,44x
Nbr of Employees 13 600
Free-Float 99,9%
Chart GILEAD SCIENCES, INC.
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | GILD | US3755581036 | MarketScreener
Technical analysis trends GILEAD SCIENCES, INC.
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Last Close Price 71,38 $
Average target price 76,38 $
Spread / Average Target 7,00%
EPS Revisions
Managers and Directors
Daniel P. O'Day Chairman & Chief Executive Officer
Andrew D. Dickinson Chief Financial Officer
Merdad V. Parsey Chief Medical Officer
Flavius Martin Executive Vice President-Research
Brett A. Pletcher Secretary, Chief Compliance Officer & Executive VP
Sector and Competitors
1st jan.Capi. (M$)
GILEAD SCIENCES, INC.22.52%89 497
BIONTECH SE316.17%81 938
WUXI APPTEC CO., LTD.36.63%69 841
REGENERON PHARMACEUTICALS33.94%67 273
VERTEX PHARMACEUTICALS-22.03%47 805
BEIGENE, LTD.50.23%36 115